Tremblay Ga, Khalafaghian G, Legault J, Nielsen P, Bartlett Aj
Charles River Preclinical & Clincal Services Montréal Inc., 22022 Transcanadienne, Senneville, QC H9X3R3, Canada.
Bioanalysis. 2011 Mar;3(5):499-508. doi: 10.4155/bio.11.18.
Oligonucleotide-based therapeutics are quantified with hybridization assays in biological matrices such as plasma and tissues. Current hybridization methods do not entirely discriminate the parent compound from 5´- or 3´-N-X truncated metabolites.
A dual ligation-based hybridization assay was developed to circumvent the limitations of current assay formats. Ligation of probes at either end of the analyte is performed via a bi-enzymatic reaction consisting of polynucleotide kinase and DNA ligase. The method was validated with regard to mechanism, specificity, precision and accuracy.
The dual ligation assay is specific for the parent compound and detects the full-length product with intact 5´- and 3´-ends. The dual ligation assay can also be used to specifically determine individual metabolites in complex mixtures and is currently implemented to quantitative PCR.
基于寡核苷酸的治疗药物在血浆和组织等生物基质中通过杂交测定法进行定量。当前的杂交方法无法完全区分母体化合物与5´-或3´-N-X截短代谢物。
开发了一种基于双重连接的杂交测定法,以克服当前测定形式的局限性。通过由多核苷酸激酶和DNA连接酶组成的双酶促反应在分析物的两端进行探针连接。该方法在机制、特异性、精密度和准确性方面得到了验证。
双重连接测定法对母体化合物具有特异性,并能检测具有完整5´-和3´-末端的全长产物。双重连接测定法还可用于特异性测定复杂混合物中的单个代谢物,目前已应用于定量PCR。